Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), sold 430 shares at $0.36 ($153) on 2024-12-16, disclosed to the SEC on 2024-12-17.
Scheduled sale ($153) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.35 | 225 | $79 | 51.6% |
| 2 | $0.36 | 205 | $74 | 48.4% |
| Total | $0.35 avg | 430 | $153 | 100% |
| Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |